Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, January 1999, p. 73-78, Vol. 6, No. 1
Immunology Branch,1
and
Office of the Director,4
Division of AIDS, Sexually Transmitted Diseases, and
Tuberculosis Laboratory Research, and Investigation and Prevention
Branch, Hospital Infections Program,2 National
Center for Infectious Diseases Centers for Disease Control and
Prevention, Public Health Service, Atlanta, Georgia 30333 and
Bamrasnaradura Infectious Diseases Hospital, Nonthaburi,
Thailand3
Received 1 May 1998/Returned for modification 13 August
1998/Accepted 2 October 1998
Opportunistic infections (OI) and the human immunodeficiency virus
(HIV) cause significant morbidity and mortality in developing countries. Immune cell and cytokine profiles may be related to the type
and course of OI and to the OI-HIV interaction. Examining cell-specific
cytokine production ex vivo has only recently become feasible. In
Thailand, 53 febrile, hospitalized adults were enrolled in a study of
the immune correlates of bloodstream infections (BSI). On
site, blood cells were stimulated ex vivo. Cell-surface antigens and
eight intracellular cytokines were subsequently analyzed using flow
cytometry to determine associations with mortality and the organism
causing the BSI. By logistic regression analysis, the percentage of
CD3+ CD16/56+ cells making tumor necrosis
factor alpha (TNF- Opportunistic infections (OI) are
major causes of morbidity and mortality in human immunodeficiency virus
(HIV)-infected persons. The interaction between OI and HIV may be a
critical factor in disease pathogenesis and outcome. For example, in
the United States, the death rates from nontuberculous mycobacteria and
cryptococcoses are, respectively, 18.5- and 4.3-fold higher than
predicted, secondary to the HIV epidemic (26). It has been
postulated that cytokines are important determinants of outcome for
infectious diseases and, particularly, for the interaction between HIV
and OI (21).
Various immune cells can produce one of at least three patterns of
cytokines (7, 10, 20). The type I pattern is associated with
the production of interleukin-2 (IL-2, tumor necrosis factor alpha
(TNF- We have adapted recently developed flow cytometric techniques to
evaluate immune cell-surface antigens and intracellular cytokines in
patients at field settings in developing countries (reference 11 and unpublished data). For the present study, we
used these adapted techniques to assess a random sample of febrile
patients at one hospital in Thailand. Immune parameters were assessed
for blood drawn at the time of blood culture. We hypothesized that certain parameters, especially certain intracellular cytokines and/or
cytokine patterns, might be predictive of one or both of the following:
(i) survival and (ii) the organisms cultured from the blood. We
included in our analyses key surface antigens defining various cell
populations: a spectrum of type I and type II cytokines, in
combinations permitting differentiation of type 0 cells producing both
types of cytokines; regulatory cytokines such as IL-12; and surface
molecules associated with the immune responses to mycobacterial and
bacterial infections (CD14 and CD1) (Table
1).
1071-412X/99/$00.00+0
Immune Determinants of Organism and Outcome in
Febrile Hospitalized Thai Patients with Bloodstream
Infections

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
) (P = 0.033) and the percentage
of CD3
CD16/56+ cells (NK)
(P = 0.032) were related to HIV positivity. Lymph node
enlargement with HIV infection and the percentage of
CD3+ CD16/56+ making TNF-
were predictive of
death. A lower percentage of CD3+ CD8+
lymphocytes making interleukin-8 (IL-8)
(P = 0.005), fewer monocytes expressing CD14
(P = 0.009), and the percentage of CD3+
CD8+ cells producing gamma interferon (P = 0.011) were associated with blood culture positivity and the causative
organism. For every one point decrease in the percentage of
CD3+ CD8+ cells making IL-8, the likelihood of
a positive culture increased 23%; for every one point decrease in the
percentage of monocytes expressing CD14, the likelihood of a positive
culture increased by 5%. Only a few immune cell types and three of
their related cytokines were significantly associated with HIV disease
outcome or the BSI organism. These cell types did not include
CD3+ CD8
cells (a surrogate for
CD4+ cells), nor did they involve cytokines
associated with a type I to type II cytokine shift, which might
occur with advancing HIV infection. These associations
support the premise that CD8+ and CD16/56+
lymphocytes play significant roles in HIV and type I infections.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
), TNF-
, and gamma interferon (IFN-
); it is induced by
IL-12 and potentiates cellular and/or cytotoxic immunity. The type II
pattern is associated with IL-4, IL-6, and IL-10 and supports humoral
immunity in response to bacterial, some viral, and some parasitic
infections (21). The type 0 pattern represents a
mixed response pattern. Animal studies support the premise that
cytokine profiles are related to the occurrence and outcome of
infection for a number of intracellular and extracellular pathogens
(7). Whether this holds true in humans has not been as
well investigated. Minimal and sometimes conflicting data broadly
suggest that a type I response leads to granuloma formation in
mycobacterial infection and clearing of trypanosomes; a type II or a
mixed pattern may be associated with symptomatic or disseminated
mycobacterial disease (7, 22, 23, 30). Cytokine profiles and
HIV infection have been investigated but conclusions vary (5, 10,
18). Certain OI, especially mycobacterial and fungal, potentiate
HIV disease; however, the cytokine determinants of this effect are not
clear (8, 9, 23, 30). Previous studies of cytokines in
humans have generally assessed cloned cells or extracellular, i.e.,
pleural fluid or plasma, cytokines. These may not accurately reflect
the immune profiles of the in vivo microenvironment in which cytokines
work. Data are also conflicting concerning the relative
importance of various immune cells, including natural killer (NK)
cells, cytotoxic T lymphocytes, and monocytes, in these same infections
in humans (2-4, 6, 12, 13, 15, 17, 22). The study described
herein is the first to assess intracellular cytokine profiles and
surface molecules in peripheral blood cells of patients with acute
bloodstream infections (BSI).
TABLE 1.
Analysis panel for flow cytometric evaluation of
surface and cytoplasmic antigensa
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Patients.
At the Bamrasnaradura Infectious Diseases
Hospital, Nonthaburi, Thailand, 246 consecutive febrile (oral
temperature,
38°C), hospitalized adult patients were enrolled
between 12 February and 4 April 1997 in a study to assess the causes of
BSI in developing countries. Of these participants, a random sample of
53 individuals also had immune studies done, as described below. This
subset was comparable to the entire study population (Table
2). Several members of the subset were
recruited each day throughout the entire course of the study. The study
protocol was approved by the Centers for Disease Control and Prevention
(CDC) and hospital institutional review boards, and informed consent
was obtained from all patients. Complete blood count and differential
and HIV antibody testing were done at the hospital, a medical history
was obtained, and a physical examination was performed by one of the
investigators (L.A., C.M., or S.R.). (As in most, if not all,
developing countries at this time, HIV-infected persons in this study
were not receiving antiviral therapies nor being monitored for CD4
counts or HIV viral titers; these capabilities were not available at
this Thai hospital or in this area of Thailand at the time of this
study.) Clinical data analyzed included HIV antibody status; acute and chronic symptoms of cough, fever, chills, and diarrhea; respiratory and
heart rates on admission; and the clinical presence or absence on
admission of candidiasis, oral leukoplakia, Kaposi's sarcoma, lymph
node enlargement (LNE, defined as cervical lymph nodes being palpable
bilaterally), hepatosplenomegaly, pulmonary symptoms, and a
Mycobacterium bovis BCG scar. Each patient enrolled in the study was monitored daily as an inpatient, and their clinical course
and outcome (survival or mortality) were recorded.
|
Laboratory procedures. (i) Blood cultures. Blood cultures were performed as previously described (1). The commercially prepared biphasic (broth-agar) systems Septi-Chek and Myco-Chek (Becton Dickinson Microbiology Systems Sparks, Md.) were used for aerobic bacterial and mycobacterial blood cultures, respectively. Briefly, 20 ml of blood was obtained and 10 ml was inoculated into a Septi-Chek bottle at the bedside and 10 ml was inoculated into a lysis centrifugation tube (Isolator; Wampole Laboratories, Cranberry, N.J.) system from which the pellet was inoculated onto standard medium. All cultures were incubated at 35°C and examined daily for 7 days, and organisms were identified to the species level by standard methods. These culture techniques have been shown previously to detect nearly all pathogenic bacteria, fungi, and mycobacterium species (31).
(ii) Cytokine stimulation. Reagents and concentrations used included phorbol 12-myristate 13-acetate (PMA) (Sigma Chemical Co., St. Louis, Mo.), 200 ng/ml; brefeldin A (BFA) (Sigma), 40 µg/ml; ionomycin (Sigma), 4 µg/ml; and ORTHO PermeaFix (ORTHO Diagnostics, Inc., Raritan, N.J.). Two milliliters of blood was collected in heparinized vacutainers and used directly in a whole-blood assay. Blood was stimulated for 5 h with PMA and ionomycin in the presence of BFA and two ml of RPMI 1640 with 2 mM L-glutamine. ORTHO PermeaFix was then added, followed by a buffered saline wash; all tubes were shipped at 4 to 8°C to the CDC for further analyses, which were done within 2 weeks. Stimulation was done because extensive published data, including our own, indicate a general lack of detectable intracellular cytokines in unstimulated human periphiperal blood mononuclear cells (11, 24).
Flow cytometric reagents.
Fluorescein isothiocyanate
(FITC)-conjugated, phycoerythrin (PE) conjugated, PE-cyanine 5 (PECy5)-conjugated, peridinin chlorophyll protein (Per CP)-conjugated,
or allophycocyanin (APC)-conjugated, murine monoclonal antibodies (MAb)
(Table 1) were obtained from (i) Becton Dickinson (BD) Immunocytometry
Systems, San Jose, Calif. (CD8-FITC and -PE [clone SK1], CD3-PerCP
and -APC [clone SK7], CD4-APC [clone SK3], CD45-FITC [clone 2D1],
CD19-APC [clone SJ25C1], CD14-PE [clone M0P9], CD69 [clone L78],
T-cell antigen receptor 
chains-FITC [clone 11F2], CD16-PE
[clone B73.1], and CD56 [clone MY31]); (ii) PharMingen, San Diego,
Calif. (CD8-PECy5 [clone RPA-T8], IL-4-PE [clone 8D4-8], IL-8-PE
[clone G265-8], IL-10-PE [clone JES3-9D7], and TNF-
-PE [clone
359-81-11]); (iii) Research and Diagnostics, Minneapolis, Minn.
(IL-6-PE [clone 1927.311]); (iv) Immune Source, Reno, Nev. (CD8-APC
[clone KL.12], IL-12-FITC [clone I.A1], TNF-
-FITC [clone
DTX.34], and IFN-
-APC [clone 13.TR]); (v) Seikagaku, Tokyo, Japan
(CD1c [clone HLT3-104D]); and (vi) Sigma (microtubulin [clone DM1A]
custom conjugated to FITC by CalTag, South San Francisco, Calif.).
Isotype controls were obtained from BD. NK cells were defined as
lymphocytes negative for CD3 and positive for CD16 and/or CD56; cells
positive for both CD3 and CD16 and/or CD56 are referred to herein as
CD3+ CD16/56+. All staining was done
postpermeabilization, and thus, staining would detect both surface and
cytoplasmic CD3.
, and 53.7% ± 18.8% and 53.5% ± 17.8% of CD8+
lymphocytes produced IFN-
.
Flow cytofluorometry.
All staining was done after
permeabilization, fixation, and shipment, at room temperature for 30 min in the dark. Staining was followed by a buffered saline wash.
Four-color cytofluorometry was done by using a FACSort cytofluorometer
and CellQuest software (BD). From 20,000 to
50,000 ungated
events were collected from each tube in the panel (Table 1).
Lymphocytes were defined on the basis of forward and side scatter, and
monocytes were defined on the basis of the forward and side scatter of
CD14+ cells (tube no. 2). Isotype controls were used to set
quandrants for cytokine assessments.
Analytical and statistical techniques.
Analyses were done
for all lymphocytes, CD3+ lymphocytes, monocytes, and
depending upon the reagent tube (Table 1), CD3+
CD8
lymphocytes, CD3+ CD8+
lymphocytes, CD19+ lymphocytes, CD3+
CD16/56+ cells and/or NK cells. Downmodulation of some
surface receptors routinely occurs with this stimulation protocol, with
CD4 downmodulation being greater than that of CD45, CD3, or CD8. These
variables were therefore used only for gating and not for analysis.
Univariate statistical comparisons were made for various cell
populations, comparing findings for various dichotomized dependent
variables, as described below. For example, we compared the percentage
of CD3+ CD8+ lymphocytes producing IFN-
in
participants who died to the percentage of CD3+
CD8+ lymphocytes producing IFN-
in participants who
survived. Proportions were compared by using Fisher's exact test.
Further analyses were done to assess two key dependent variables:
clinical outcome (alive versus dead) and cause of BSI. The cause of BSI
was analyzed three different ways: (i) any organism isolated versus no
organism isolated; (ii) a type I organism isolated versus all other
culture results, with type I organism defined as mycobacterium,
cryptococcus, or fungus; and (iii) the specific organism isolated
versus all other culture results. Analyses were also done assessing LNE
and HIV infection as dependent variables. For each dependent variable, univariate analyses were done using Kruskal-Wallis tests to determine which immune parameters, separately, were associated with the dependent
variable. The immune parameters found to be significant at the 0.1 level were included in a stepwise logistic regression model. All
analyses were done using SAS statistical software (Cary, N.C.). Six
patients with bacteremia were not included in this analysis because
they had polymicrobial infections; these included Salmonella
spp.-Mycobacterium avium (2),
Salmonella spp.-other acid-fast bacteria (1),
Salmonella spp.-Pseudomonas spp. (1), Pseudomonas spp.-Cryptococcus spp.
(1), and S. aureus-M. avium (1).
| |
RESULTS |
|---|
|
|
|---|
Determinants of clinical outcome: LNE, HIV positivity, and TNF-
production by CD3+ CD16/56+. (i) Clinical
correlations.
Of the clinical findings evaluated, only LNE was
associated with immune findings or clinical outcome. LNE occurred only
in HIV-positive participants: 27 of 43 (63%) of HIV-positive
participants had LNE compared to 0 of 10 (0%) of HIV-negative
participants (P < 0.001). For HIV-positive
participants, two variables in a logistic regression analysis were
significantly related to LNE: the percentage of lymphocytes expressing
the B-cell marker CD19 (P = 0.011) (for participants
with LNE, 9.2% of lymphocytes were CD19+; for participants
without LNE, 12.7% of lymphocytes were CD19+) and the
percentage of CD3+ CD16/56+ cells making
TNF-
(P = 0.012) (for participants with LNE, 4.5% of CD3+ CD16/56+ lymphocytes made TNF-
; for
participants without LNE, 20.3% of CD3+
CD16/56+ lymphocytes did so).
(ii) Correlates of HIV infection.
In a logistic regression
analysis, only two variables were significantly associated with HIV
positivity: the percentage of CD3+ CD16/56+
cells making TNF-
(P = 0.033) (7.0% for
HIV-positive participants versus and 25.1% for HIV-negative
participants) and the percentage of lymphocytes that were NK
(P = 0.032) (2.4 versus 0.6% for HIV-positive versus
-negative participants, respectively).
(iii) Correlates of outcome.
None of 10 HIV-negative patients
versus 13 of 43 (30%) HIV-positive patients died (P = 0.096). Within the HIV-positive patient group, 11 of 27 (41%)
participants with LNE died compared to 2 of 16 (13%) without LNE
(P = 0.086). The presence of a positive blood culture
was not significantly related to mortality among all participants
(P = .712) (Table 3) or
within the HIV-positive subgroup: 8 of 28 (29%) for whom an organism
was isolated died versus 5 of 15 (33%) of those with a negative blood
culture (P = 0.742). No particular pathogen or type of
organism (type I organism versus bacteria versus no organism) was
associated with increased mortality in a logistic regression model. In
univariate analysis, several immune variables were associated with
survival (Table 4); however, in logistic
regression analysis, no combination was significant. Since the
percentage of CD3+ CD16/56+ cells making
TNF-
and the variables of LNE, HIV infection, and outcome were all
interrelated, we examined these variables in terms of one another.
TNF-
production by CD3+ CD16/56+ cells was
significantly and inversely related to LNE (P = 0.001) and tended also to be inversely related to HIV positivity and survival,
although the latter associations did not reach significance (Table
5). This interrelationship was not found
for NK cells or all CD3+ lymphocytes.
|
|
|
Determinants of culture positivity and organism isolated: CD14
expression by monocytes and IL-8 and IFN-
production by
CD3+ CD8+ lymphocytes.
Study participants
had BSI which were due to a wide variety of pathogens (Table 3).
HIV-infected patients were significantly more likely to have a positive
blood culture: 28 of 43 (65%) HIV-positive versus 1 of 10 (10%)
HIV-negative patients had positive blood cultures (P = 0.003). (The one HIV-negative patient with a positive blood
culture had a fungal infection). LNE was not associated with blood
culture positivity: 16 of 29 (55%) HIV-positive participants with LNE
versus 13 of 26 (50%) without LNE had an organism isolated (P = 0.790). By univariate analysis, 11 immune
variables were significantly associated with the type of organism
isolated from the blood (Table 6).
|
(i) Isolation of any organism.
In a logistic regression model,
culture positivity was associated with a lower percentage of
CD3+ CD8+ lymphocytes making IL-8
(P = 0.005 for those with a positive blood culture
versus those with a negative blood culture) and fewer monocytes
(defined by scatter pattern) expressing CD14 on their surface
(P = 0.009 for those with a positive blood culture versus those with a negative blood culture). For every one point decrease in the percentage of CD3+ CD8+ cells
making IL-8, the likelihood of a positive culture increased 23%; for
every decrease by one point in the percentage of monocytes expressing
CD14, the likelihood of a positive culture increased by 5%. In the
model, culture positivity was also statistically related to the
percentage of CD3+ CD8+ cells producing IFN-
(P = 0.011). These same variables remained in the model
when HIV-positive patients were analyzed separately.
(ii) Type I infection versus bacterial infection or negative blood
culture.
In a logistic regression model, type I infection was
associated with IL-8 and IFN-
production by CD3+
CD8+ lymphocytes and CD14 expression on monocytes. The
percentages of CD3+ CD8+ cells producing IL-8
and the percentages of monocytes expressing CD14 were highest for
patients with negative cultures and lowest for patients with bacterial
infections (Table 6). Within the type I group, those with an
M. tuberculosis infection had the lowest median
percentage of monocytes expressing CD14: M. tuberculosis 1.5%; M. avium, 21.7%;
cryptococcus, 8.2%; fungi, 14.1% (P = 0.043 for
M. tuberculosis versus all other culture results). Type
I infection was also associated with the highest percentage of
CD3+ CD8+ cells producing IFN-
(Table 6),
especially in non-M. tuberculosis infections:
M. avium, 37.1%; other acid-fast bacteria,
100%; M. tuberculosis 19.4%; cryptococcus,
35.1%; fungis: 23.9%.
(iii) Bacterial infection versus type I or negative culture. Only five bacterial BSI occurred in the absence of some other coinfection. By univariate analysis, a number of variables were shown to be significantly associated with bacterial infections; all these are shown in Table 6. No combination of variables was significant in logistic regression analysis.
| |
DISCUSSION |
|---|
|
|
|---|
Mycobacteria, fungi, and bacteria can cause localized or systemic
disease. A number of immune parameters have been suggested as being
potentially important for the occurrence, presentation, and outcome of
these diseases, including various cytokines and cytokine profiles,
T-cell antigen receptor 
+ cells, cytotoxic T cells,
NK cells, CD1c expression on antigen-presenting cells, and CD14
expression on monocytes-macrophages. We had a unique opportunity to
assess the relative importance of these parameters in febrile
hospitalized patients with and without confirmed BSI. Most of these
patients were also infected with HIV. Type I BSI are extremely unusual
in non-HIV-infected persons, precluding our examination of
these infections in a larger group of non-HIV-infected persons.
Although our numbers are not large and extrapolation of these results
beyond HIV-infected persons should be done with caution, this study
represents by far the largest group of patients with type I BSI for
which cytokine and immune cellular evaluation has been done.
As would be expected, HIV status was associated with clinical outcome
and culture positivity, although the first association did not reach
statistical significance. Only a few cell types, cytokines, and surface
molecules were related to HIV positivity, mortality within the
HIV-positive population, or organism isolation. Most striking were two
discrete clusters of association: (i) the percentage of
CD3+ CD16/56+ cells producing TNF-
associated with LNE, HIV positivity, and mortality and (ii) the
percentage of CD3+ CD8+ cells making IL-8 or
IFN-
and the percentage of monocytes expressing CD14 associated with
the organism isolated from the blood. Of note was the lack of an
association in either cluster with lymphocyte counts or percentages.
Also of note is that the cells and parameters of importance in both
clusters were not those hypothesized as being associated with advancing
HIV disease, i.e., a shift from type I to type II cytokines in
CD4+ cells, herein examined as those being CD3+
CD8
.
In the first cluster of associations, the risk of death increased
with HIV positivity, LNE, and a decreasing percentage of CD3+ CD16/56+ lymphocytes producing TNF-
.
This set of associations suggests that mortality was due to a
potentiation of the HIV disease process but not to a type I to type II
shift in CD4+ cells. This potentiation may have been
related in some way to the BSI, (e.g., to the relative virulence of the
BSI) but was not related to the type of BSI per se. Further, one is
lead to conjecture as to whether, in the enlarged lymph nodes as in the blood, these cells were involved in the immune system's attempt to
contain the HIV infection. If so, the one deceased participant who did
not have LNE might have represented a case of lymph node exhaustion or atrophy.
NK cells were once thought to play a central role in determining the
initial T-cell cytokine response pattern to infection (7,
28). In our study population, they were significantly related to
HIV infection but not to BSI. More striking, we found a significant
inverse association between TNF-
production by CD3+
CD16/56+ cells, LNE, and mortality. Most NK cells do not
express CD3, although CD3 expression has been occasionally reported in
the context of tumors or HIV infection (29). Also, our
permeabilization procedure would lead to staining of cytoplasmic, as
well as surface, CD3; cytoplasmic CD3 in surface CD3
NK
cells has not been examined. Our data suggest that surface and/or
cytoplasmic CD3+ cells positive for CD16 and/or CD56 may
represent an important and currently unexamined cell population in
regard to HIV infection. Further, the inverse association we found
between TNF-
production by these cells, LNE, and death may be highly
pertinent to the current controversy over the relative benefits and
harm caused by TNF-
in the context of HIV and OI (8, 9, 14, 19, 22, 23, 30). Our data indicate that TNF-
production by CD3+ CD16/56+ may be associated with a more
positive clinical outcome, especially for patients with LNE. Thus, use
of medications known to affect TNF-
production, e.g., thalidimide or
drugs specifically intended to inhibit TNF-
production, might lead
to adverse outcomes in at least some persons with HIV infection.
The second cluster of immune findings, associated with blood
culture positivity and with the particular organism isolated, involved
monocytes and CD8+ lymphocytes (often referred to as
cytotoxic T cells, although CD4+ cells can also exhibit
cytotoxic activity). Specifically, these significant parameters
included (i) the percentage of monocytes expressing CD14, (ii) the
percentage of CD8+ lymphocytes producing IL-8, and (iii)
the percentage of CD8+ lymphocytes producing IFN-
. Each
was included in the immune evaluation because previous studies have
suggested they might be related to various organisms causing BSI. CD14
is a monocyte-macrophage surface molecule that can interact with both
gram-negative bacterial lipopolysaccharide and with mycobacterial
lipoarabinomannan (13, 25). IL-8 is a cytokine frequently
studied in relation to bacterial sepsis but only infrequently evaluated
in type I infection (16, 22). IFN-
is a cytokine
disproportionately produced by CD8+ cells compared to that
produced by CD4+ cells, even in healthy humans,
(11) and is felt by some to play an important role in HIV
infection (3, 4, 12), toxoplasmosis (27), and
murine M. tuberculosis (22). We found these
three parameters varied in relation to the presence or absence of a positive blood culture and also in relation to the type of organism isolated from the blood. If these results, based on a single group of
patients, can be replicated in other groups, they may prove useful in
predicting the likelihood of a blood culture becoming positive and even
what type of organism will be isolated from the blood. This could
assist in decisions concerning presumptive therapy for HIV-related OI
that usually require prolonged culture, such as mycobacteria.
In summary, many cytokines and immune cell types have been suggested as being important determinants of disease and outcome in OI. We wished to directly examine the immune cells responding to an infection. Thus, we evaluated peripheral blood immune cells of patients with BSI rather than those of patients with localized infections. In this study population, we found that only a few immune cell types and only three of their related cytokines were significantly associated with disease outcome and the infecting organisms. These findings were not suggestive of a type I to type II cytokine shift in advancing HIV disease but, rather, supported the importance of CD16/CD56+ and CD8+ cells in HIV and type I infections.
| |
ACKNOWLEDGMENTS |
|---|
We are extremely grateful to K. Leigh Inge for technical assistance and to L. Barth Reller, Celeste McKnight, Terry C. Byrne, and Rachel Addison, for confirming the identification of bacterial, fungal, and mycobacterial isolates.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Mailstop A-25, Immunology Branch, DASTLR, NCID, CDC, 1600 Clifton Rd., N.E.; Atlanta, GA 30333. Phone: (404) 639-3919. Fax: (404) 639-2108. E-mail: JMJ1{at}CDC.gov.
Present address: Tufts University, Medford, MA.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Archibald, L. K., M. O. den Dulk, K. J. Pallangyo, and L. B. Reller. 1998. Fatal mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults, Dar es Salaam, Tanzania. Clin. Infect. Dis. 26:290-296[Medline]. |
| 2. | Bermudez, L. E. M., and L. S. Young. 1991. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J. Immunol. 146:265-270[Abstract]. |
| 3. | Breen, E. C., J. F. Salazar-Gonzalez, L. P. Shen, J. A. Kolberg, M. S. Urdea, O. Martinez-Maza, and J. L. Fahey. 1997. Circulating CD8 T cells show increased interferon-gamma mRNA expression in HIV infection. Cell. Immunol. 178:91-98[Medline]. |
| 4. | Caruso, A., A. D. Canaris, S. Licenziati, A. Cantalamessa, S. Folghera, M. A. Lonati, G. dePanfilis, G. Garotta, and A. Turano. 1995. CD4+ and CD8+ lymphocytes of patients with AIDS synthesize increased amounts of interferon-gamma. J. Acquired Immune Defic. Syndr. 10:462-470. |
| 5. | Clerici, M., and G. M. Shearer. 1993. A Th1 to Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today 14:107-111[Medline]. |
| 6. | Djeu, J. Y., M. B. Michelini-Norris, and D. K. Blanchard. 1994. Macrophage-natural killer cell interactions in resistance to mycobacteria. Immunol. Ser. 60:225-231[Medline]. |
| 7. | Fresno, M., M. Kopf, and L. Rivas. 1997. Cytokines and infectious diseases. Immunol. Today 18:56-58[Medline]. |
| 8. | Harrison, T. S., S.-H. Nong, and S. M. Levitz. 1997. Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J. Infect. Dis. 176:485-491[Medline]. |
| 9. |
Jacobson, J. M.,
J. S. Greenspan,
J. Spritzler,
N. Ketter,
J. L. Fahey,
J. B. Jackson,
L. Fox,
G. J. Vasquez, and D. A. Wohl.
1997.
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection.
N. Engl. J. Med.
336:1487-1491 |
| 10. | Jason, J., L. A. Sleeper, S. M. Donfield, J. Murphy, I. Warrier, S. Arkin, and B. Evatt. 1995. Evidence for a shift from a type I lymphocyte pattern with HIV disease progression. J. Acquired Immune Defic. Syndr. 10:471-476. |
| 11. | Jason, J., and J. Larned. 1997. Single-cell cytokine profiles in normal humans: comparison of flow cytometric reagents and stimulation protocols. J. Immunol. Methods 207:13-22[Medline]. |
| 12. |
Jassoy, C.,
T. Harrer,
T. Rosenthal,
B. A. Navia,
J. Worth, and R. P. Johnson.
1993.
Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF- ), and TNF- when they encounter their target antigens.
J. Virol.
67:2844-2852 |
| 13. | Keller, R., R. Keist, and P. Joller. 1995. Macrophage response to microbial pathogens: modulation of the expression of adhesion, CD14, and MHC class II molecules by viruses, bacteria, protozoa and fungi. Scand. J. Immunol. 42:337-344[Medline]. |
| 14. | Klausner, J. D., S. Makonkawkeyoon, P. Akarasewi, K. Nakata, W. Kasinrerk, L. Corral, R. L. Dewar, H. C. Lane, V. H. Freedman, and G. Kaplan. 1996. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 11:247-257[Medline]. |
| 15. | Koziel, M. J., D. Dudley, N. Afdhal, A. Grakoui, C. M. Rice, Q. L. Choo, M. Houghton, and B. D. Walker. 1995. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J. Clin. Invest. 96:2311-2321. |
| 16. | Kragsbjerg, P., H. Holmberg, and T. Vikerfors. 1996. Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand. J. Infect. Dis. 28:391-398[Medline]. |
| 17. | Lorgat, F., M. M. Keraan, P. T. Lukey, and S. R. Ress. 1992. Evidence for in vivo generation of cytotoxic T cells. PPD-stimulated lymphocytes from tuberculous pleural effusions demonstrate enhanced cytotoxicity with accelerated kinetics of induction. Am. Rev. Respir. Dis. 145:418-423[Medline]. |
| 18. |
Maggi, E.,
M. Mazzetti,
A. Ravina,
F. Annunziato,
M. de Carli,
M. P. Piccinni,
R. Manetti,
M. Carbonari,
A. M. Pesce,
G. del Prete, and S. Romagnani.
1994.
Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells.
Science
265:244-248 |
| 19. | Matsuyama, T., N. Kobayashi, and N. Yamamoto. 1991. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 5:1405-1417[Medline]. |
| 20. | Mossmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2357[Abstract]. |
| 21. | Mossmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 17:138-146[Medline]. |
| 22. | Rom, W. N., N. Schluger, K. Law, R. Condos, Y. Zhang, M. Weiden, T. Harkin, and K.-M. Tchou-Wong. 1995. Human host response to Mycobacterium tuberculosis. Schweiz. Med. Wochenschr. 125:2178-2185[Medline]. |
| 23. | Rook, G. A. W. 1994. Macrophages and Mycobacterium tuberculosis: the key to pathogenesis. Immunol. Ser. 60:249-261[Medline]. |
| 24. | Sander, B., J. Andersson, and U. Andersson. 1991. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunolog. Rev. 119:65-93[Medline]. |
| 25. | Savedra, R., Jr., R. L. Delude, R. R. Ingalls, M. J. Fenton, and D. T. Golenbock. 1996. Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J. Immunol. 157:2549-2554[Abstract]. |
| 26. | Selik, R. M., J. M. Karon, and J. W. Ward. 1997. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J. Infect. Dis. 176:632-636[Medline]. |
| 27. | Shirahata, T., T. Yamnashita, C. Ohta, H. Goto, and A. Nakane. 1994. CD8+ T lymphocytes are the major cell population involved in the early gamma interferon response and resistance to acute primary Toxoplasma gondii infection in mice. Microbiol. Immunol. 38:789-796[Medline]. |
| 28. | Swain, S. L. 1995. T-cell subsets. Who does the polarizing? Curr. Biol. 5:849-851[Medline]. |
| 29. | Tambussi, G., V. Albarello, A. Gori, C. Bisson, and A. Lazzarin. 1994. Transitory expansion of a CD3+TcR gamma/delta+CD16+ lymphocytic population in two patients with advanced human immunodeficiency virus infection and high levels of natural killer activity. AIDS Res. Hum. Retroviruses 10:711-715[Medline]. |
| 30. | Wallis, R. S., and J. J. Ellner. 1994. Cytokines and tuberculosis. J. Leukocyte Biol. 55:676-681[Abstract]. |
| 31. | Weinstein, M. P. 1996. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin. Infect. Dis. 23:40-46[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |